A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjunctivitis
Latest Information Update: 06 Jul 2011
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic conjunctivitis; Allergic rhinitis; Rhinoconjunctivitis
- Focus Adverse reactions
Most Recent Events
- 06 Jul 2011 New trial record